Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SUBLOCADE Clear all
Recruiting Not applicable Interventional

Enhancing Addiction Treatment Through Psychoeducation

NCT07178158
View directory record Official record
Conditions
Substance Use Disorders
Interventions
Installing the Metacognium software app, Continue treatment as usual
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Not applicable Interventional Results available

PRimary Care Opioid Use Disorders Treatment (PROUD) Trial

NCT03407638
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
PROUD Intervention
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
16 Years to 90 Years
Enrollment
377,373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Miami, Florida • Detroit, Michigan • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Phase 2 Interventional

Buprenorphine Maintenance for Opiate Dependence - 6

NCT00000357
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1993
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 30, 2026, 3:11 PM EDT
Recruiting Not applicable Interventional

Adaptive Decision Support for Addiction Treatment Master

NCT06799117
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
EMBED CDS, Nurse prompt to complete COWS, Provider Prompt, Patient facing materials, Optimized EMBED, Name of Intervention
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Guilford, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions

NCT01157169
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence

NCT01848054
View directory record Official record
Conditions
Opioid-Related Disorders, Opiate Dependence
Interventions
Buprenorphine/naloxone sublingual tablets, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • Haleyville, Alabama • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Phase 2 Interventional Results available

Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

NCT01262092
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
Interventions
Buprenorphine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 30, 2026, 3:11 PM EDT
Terminated Phase 4 Interventional Results available

Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization

NCT05118204
View directory record Official record
Conditions
Substance Use Disorders, Opioid-use Disorder, Chronic Pain
Interventions
BUP microdose induction, TAU, Linkage to outpatient BUP treatment
Drug · Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 3:11 PM EDT
Completed No phase listed Observational

Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions

NCT04049799
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Withdrawal, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome
Interventions
Medically-supervised withdrawal, Opioid agonist treatment, Comprehensive clinical care
Other · Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Asheville, North Carolina • Chapel Hill, North Carolina • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 30, 2026, 3:11 PM EDT
Not listed Not applicable Interventional

Serratus Anterior Plane Block With and Without Adjuvants in Video-assisted Thoracoscopy

NCT05090761
View directory record Official record
Conditions
Post Operative Pain, Acute
Interventions
Bupivacaine 0.25% Injectable Solution, Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pontiac, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 30, 2026, 3:11 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Social Functioning in Opioid Use Disorder

NCT07044466
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
CBT4CBT-Buprenorphine
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders

NCT03232346
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Vivitrol, Buprenorphine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Phase 2Phase 3 Interventional

EXHIT ENTRE Comparative Effectiveness Trial

NCT04345718
View directory record Official record
Conditions
Substance Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
Extended Release Buprenorphine, Treatment as Usual
Drug
Lead sponsor
Gavin Bart
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Not applicable Interventional

Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone Recipients

NCT02093559
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Overdose
Interventions
Brief counseling Intervention
Behavioral
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 30, 2026, 3:11 PM EDT
Recruiting Phase 2 Interventional

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

NCT05778591
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Buprenorphine 0.15 MG [Belbuca]
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Not applicable Interventional

Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia

NCT00539123
View directory record Official record
Conditions
Opiate Dependence
Interventions
behavioral drug and HIV risk reduction counseling (BDRC), abstinence-contingent buprenorphine (ACB)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Not applicable Interventional Results available

HIV, Buprenorphine, and the Criminal Justice System

NCT01550341
View directory record Official record
Conditions
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
Interventions
Buprenorphine/naloxone, Placebo Oral Tablet
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 30, 2026, 3:11 PM EDT
Recruiting Phase 1 Interventional

Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine

NCT04161066
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin with facilitated counseling
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Phase 1 Interventional

Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults

NCT01046539
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
RDC-0313 + Buprenorphine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.

NCT03212794
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Recovery coach
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Not applicable Interventional

The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions

NCT04245423
View directory record Official record
Conditions
Opioid-use Disorder, Mental Health Conditions
Interventions
Collaborative Care for Opioid Use Disorders and Mental Health Conditions, Augmented Usual Care, Collaborative Care for Opioid Use Disorders and Mental Health Conditions Plus Certified Recovery Specialists
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Phase 2 Interventional

Buprenorphine Maintenance for Opioid Addicts - 2

NCT00000203
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1

NCT00023283
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Substance Abuse, Intravenous
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 30, 2026, 3:11 PM EDT
Completed Phase 1Phase 2 Interventional

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence

NCT03015246
View directory record Official record
Conditions
Heroin Dependence, Opioid Use Disorder
Interventions
Extended release morphine, Buprenorphine/Naloxone low dose, Buprenorphine/Naloxone moderate dose, Buprenorphine/Naloxone high dose, Active stressor, Placebo stressor
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 30, 2026, 3:11 PM EDT